Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Aurisco Pharmaceutical Co Ltd

605116:SHH

Aurisco Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)21.86
  • Today's Change-0.29 / -1.31%
  • Shares traded2.44m
  • 1 Year change-11.68%
  • Beta0.2353
Data delayed at least 15 minutes, as of Nov 01 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aurisco Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of specialty active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The Company's main products are respiratory, cardiovascular, anti-infective and nervous system drugs, including flumethasone, fluticasone propionate, eplerenone, tenofovir, pregabalin and other APIs and intermediates. The Company distributes its products in domestic market and to overseas markets.

  • Revenue in CNY (TTM)1.43bn
  • Net income in CNY340.67m
  • Incorporated1998
  • Employees1.52k
  • Location
    Aurisco Pharmaceutical Co LtdNo. 1 Longxing RoadBadu Industrial Park, Tiantai CountyTAIZHOU 317200ChinaCHN
  • Phone+86 57 683170900
  • Fax+86 57 683170900
  • Websitehttps://www.aurisco.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jiangsu Kanion Pharmaceutical Co., Ltd.4.57bn526.44m8.24bn5.44k15.711.60--1.800.9020.9027.848.850.66022.996.94840,425.307.736.6810.399.4972.4874.0211.7110.282.18--0.0025.5711.884.9423.545.33-1.8735.99
Aurisco Pharmaceutical Co Ltd1.43bn340.67m8.88bn1.52k26.913.91--6.220.81240.81243.405.580.47161.144.72939,069.6011.2312.4013.3514.3357.1651.2623.8123.052.82--0.304925.1525.2417.0237.2316.1626.54--
Shenzhen Chipscreen Biosciences Co Ltd656.24m-70.33m9.12bn1.06k--5.55--13.89-0.1709-0.17091.604.030.20222.344.47620,847.90-2.171.32-2.441.5486.2493.29-10.726.972.76-0.55840.4410.00-1.1828.81408.0923.3110.23--
Nanjing Vazyme Biotech Co Ltd1.40bn23.59m9.13bn2.70k370.882.29--6.510.06150.06153.849.970.26441.063.57519,483.100.412213.160.523715.9270.2170.501.5623.924.17--0.143632.20-63.9749.74-111.94--48.61--
GuangYuYuan Chinese Herbal Medicn Co Ltd1.24bn136.56m9.32bn1.81k68.255.95--7.520.2790.2792.533.200.50110.56472.60684,557.406.04-2.108.71-3.1672.2169.7412.05-6.000.987321.000.0267--13.56-4.53136.03-24.78-58.35--
Cansino Biologics Inc748.53m-720.11m9.57bn1.49k--2.67--12.78-2.92-2.923.0320.460.08510.63411.12501,023.80-8.41-4.27-11.09-5.5967.7141.73-98.82-27.602.27-8.750.2934---65.49163.48-63.04--30.60--
North China Pharmaceutical Co Ltd9.71bn79.38m9.69bn10.16k121.431.81--0.99880.04650.04655.683.130.44922.674.34955,385.000.6731-0.29781.54-0.704229.7935.731.50-0.59850.56091.640.6482---3.621.89100.71-49.624.22-19.73
Data as of Nov 01 2024. Currency figures normalised to Aurisco Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

3.21%Per cent of shares held by top holders
HolderShares% Held
China Asset Management Co., Ltd.as of 30 Jun 20245.60m1.42%
China Universal Asset Management Co., Ltd.as of 30 Jun 20242.30m0.58%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024816.80k0.21%
Lion Fund Management Co., Ltd.as of 30 Jun 2024800.00k0.20%
Cinda Fund Management Co. Ltd.as of 30 Jun 2024598.60k0.15%
CIB Fund Management Co., Ltd.as of 30 Jun 2024570.00k0.14%
Guotai Asset Management Co., Ltd.as of 30 Jun 2024525.70k0.13%
New China Fund Management Co., Ltd.as of 30 Jun 2024506.40k0.13%
Bank of Communications Schroder Fund Management Co., Ltd.as of 30 Jun 2024496.00k0.13%
Caitong Securities Asset Management Co., Ltd.as of 30 Jun 2024491.60k0.12%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.